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Purpose
Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor.
In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) 
HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response
(PR) with " three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine
([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT).
In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to
achieve these criteria, with the aim of improving the metastatic response rate. 
Materials and Methods
Patients with metastatic high-risk neuroblastoma who had not achieved the SIOPEN criteria
for HDT after induction received two courses of topotecan 1.5 mg/m2/day for 5 days, followed
by a 48-hour infusion of vincristine, 2 mg/m2, and doxorubicin, 45 mg/m2.
Results
Sixty-three patients were eligible and evaluable. Following two courses of TVD, four (6.4%)
patients had an overall CR, while 28 (44.4%) had a PR with a combined response rate of
50.8% (95% confidence interval [CI], 37.9 to 63.6). Of these, 23 patients achieved a
metastatic CR or a PR with " 3 mIBG skeletal areas and no bone marrow disease (36.5%;
95% CI, 24.7 to 49.6) and were eligible to receive HDT. Toxicity was mostly haematological,
affecting 106 of the 126 courses (84.1%; 95% CI, 76.5 to 90.0), and dose reduction was
necessary in six patients. Stomatitis was the second most common nonhematological tox-
icity, occurring in 20 patients (31.7%). 
Conclusion
TVD was effective in improving the response rate of high-risk neuroblastoma patients after
induction with COJEC enabling them to proceed to HDT. However, the long-term benefits of
TVD needs to be determined in randomized clinical trials.
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Introduction
Stage 4 neuroblastoma in children > 18 month of age is still
a challenging disease to treat, despite modern therapeutic
strategies, with two-thirds of patients refractory to first-line
therapy or developing disease progression or relapse after
an initial response [1,2].
Rapid COJEC (two courses of carboplatin, etoposide, vin-
cristine; four courses of cisplatin, vincristine; two courses of
etoposide, cyclophosphamide) is a time-intensive chemo-
therapy regimen administered at 10-day intervals that is
utilised by the International Society of Paediatric Oncology
Europe Neuroblastoma Group (SIOPEN) as the induction
therapy for high-risk neuroblastoma patients (SIOPEN 
HR-NBL-1) [3,4]. Incomplete metastatic response to induc-
tion therapy for high-risk neuroblastoma has been shown to
be associated with an inferior long-term outcome [5-7].
Therefore, SIOPEN elected for patients with high-risk neu-
roblastoma only proceeds to high dose therapy (HDT) if the
patients have achieved a metastatic complete response (CR)
or a “good” partial response (GPR). This is defined as at least
a 50% reduction in skeletal iodine 123-metaiodobenzylguani-
dine([123I]mIBG) positivity and ! 3 abnormal skeletal areas
on mIBG scintigraphy and no evidence of tumour on bone
marrow aspirates and trephines after rapid COJEC. The sta-
tus of the primary tumour is irrelevant to the decision to pro-
ceed to HDT. Given that with COJEC about 31% of patients
do not achieve these strict SIOPEN criteria for HDT (Laden-
stein R et al., personal communication), further strategies are
needed to improve response and increase the number of 
patients becoming eligible for HDT.
In a previous phase II study of relapsed or refractory 
patients with neuroblastoma [8], the combination of topote-
can given for 5 consecutive days prior to vincristine and dox-
orubicin administered simultaneously in a 48-hour continuous
infusion (topotecan-vincristine-doxorubicin [TVD] regimen)
showed a combined response rate (RR) of 64% CR and partial
response (PR).
Herein, we report the efficacy and toxicity of the TVD reg-
imen (clinical trials identifier, NCT00392340) given to 
improve the metastatic response in children following induc-
tion therapy in SIOPEN HR-NBL-1, facilitating them to 
receive HDT with the lowest metastatic burden.
Materials and Methods
This was an open-label, multi-centre, phase II study 
included in the therapeutic strategy of SIOPEN HR-NBL-1
protocol designed to evaluate the efficacy and toxicity of two
courses of TVD in patients with stage 4 high-risk neuroblas-
toma. Patients eligible for TVD were those in whom the best
metastatic response after induction therapy with COJEC was
a “poor” PR (PPR, defined as < 50% reduction in skeletal
mIBG positivity and/or > three areas of abnormal skeletal
uptake on mIBG scintigraphy and/or persistence of tumour
on bone marrow aspirate and trephine morphological exam-
ination), mixed response (MR), stable disease (SD), or pro-
gressive disease (PD) according to the International Neuro-
blastoma Response Criteria (INRC) [9].
Other eligibility criteria included a absolute neutrophil
count (ANC) > 1,000/µL, platelet count > 100,000/µL, crea-
tinine level < 1.5 mg/dL, total bilirubin < 1.2 mg/dL, aspar-
tate aminotransferase, and alanine aminotransferase < 2.5 SD
of the reference laboratory, and normal cardiac function on
echocardiography. Exclusion criteria included any severe
organ dysfunction, known human immunodeficiency virus
infection, hepatitis or hepatitis C virus infection and previous
treatment with doxorubicin or other treatment besides the
COJEC regimen.
According to the TVD regimen, topotecan was adminis-
tered intravenously as a 30-minute infusion in 0.9% saline in
100 mL/m2 and a dose of 1.5 mg/m2/day for 5 consecutive
days. Vincristine was administered in a 48-hour continuous
intravenous infusion at a dose of 1 mg/m2/day in 125 mL/
m2/day 0.9% saline (maximum dose, 1 mg/day), starting 1
hour after the final topotecan infusion. Doxorubicin was 
administered intravenously simultaneously with vincristine
at a dose of 22.5 mg/m2/day in 125 mL/m2/day of 0.9%
saline solution. Granulocyte-colony stimulating factor (fil-
grastim) was administered at a dose of 5 µg/kg/day subcu-
taneously starting 48 hours after the end of the TVD course
and continuing until neutrophil recovery (ANC > 2,500/µL).
Anti-emetic therapy was administered according to institu-
tional policies.
The second course of TVD was scheduled 21-28 days after
completion of the first course, following hematologic recov-
ery (ANC > 1,000/µL, platelet count > 100,000/µL), in the 
absence of clinical evidence of PD and nonhematological tox-
icity greater than grade 1, according to the Common Termi-
nology Criteria for Adverse Events (http://ctep.cancer. gov).
Febrile episodes were classified according to standard inter-
national criteria [10].
After completion of the second TVD course, the overall
and metastatic tumour response were evaluated by means of
a computed tomography or magnetic resonance imaging
scan, mIBG scintigraphy, morphological examination of bone
marrow aspirates and trephines from at least two sites 
according to the INRC criteria. However, according to the
SIOPEN HR-NBL-1 protocol, only patients achieving meta-
static CR or GPR were eligible for HDT. All other patients
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became eligible for any other salvage treatment (Fig. 1).
Surgical resection of the primary tumour was recom-
mended before HDT, if possible.
The study was approved by national or institutional ethics
committees and legal guardians and/or participants were 
required to provide informed consent prior participation.
1. Statistical methods
For this phase II study, the primary endpoint was the RR
after two courses of TVD. Achievement of either a CR, or any
PR according to the INRC [9] after two courses of TVD was
considered a success, while PD, SD, and MR were considered
failures.
The study had a two-stage design according to Simon [11],
with an accepted # error of 0.05 and a power of 90%. In this
model, a RR < 30% was not considered as interesting (P0),
while a RR " 50% was considered sufficient to accept the
treatment for further study. According to this design, it was
necessary to recruit 24 patients in the first stage, and if at least
eight responses (CR or PR) were observed, the study could
continue to a total of 63 enrolled patients.  
The percentage of patients who achieved the SIOPEN cri-
teria to proceed to HDT and the response of metastases 
according to metastatic status at study entry were also cal-
culated.
Binomial exact confidence intervals (95% CI) were calcu-
lated and reported for all response and toxicity rates. The chi
squared test or Fisher exact test, when applicable, were used
to compare categorical variables.
Results
1. Baseline characteristics
From April 2007 to October 2009, a total of 65 patients from
six European countries (30 centers) were enrolled into the
study; two of whom were subsequently excluded (one because
of stage 3 disease at diagnosis, one for insufficient data). The
characteristics of the remaining 63 (40 males, 23 females) eli-
gible and evaluable patients are summarised in Table 1. The
HR-NBL-1
Rapid
COJEC
Off study
TVD 1 TVD 2
HDT
PPR
MR
SD
PD
PPR
MR
SD
PD
CR
GPR
CR
GPR
Fig. 1. The topotecan-vincristine-doxorubicin (TVD) salvage therapy for children included in the HR-NBL-1 protocol. Patients
with persistent metastatic disease after the COJEC induction therapy of the International Society of Paediatric Oncology 
Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol were eligible for TVD therapy with the aim of eradicating the metasta-
tic disease.  Children achieving complete remission (CR) or good partial response (GPR) become eligible for consolidation
with high dose therapy (HDT) as planned by the original HR-NBL-1 protocol, all the other were considered failures. PPR,
poor partial response; MR, mixed response; SD, stable disease; PD, progressive disease.
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overall response according to INRC at study entry (i.e., after
rapid COJEC) was PPR in 40 patients (63.5%), MR in seven
(11.1%) patients, SD in 15 (23.8%) patients, and PD in one 
patient (1.6%). Of the seven patients with an overall MR 
according to INRC, six had a metastatic PPR and one had
metastatic SD. Thus, if only the metastatic response was con-
sidered, 46 children (73%) were in PPR, 16 (25.4%) had SD and
one (1.6%) had PD. With regard to the metastatic sites, 37 
patients (58.7%) had bone marrow involvement, 52 (82.5%)
had skeletal mIBG-positive metastatic disease and only one
(1.6%) had liver metastases (Table 2).
2. Antitumor activity 
According to the statistical design, after enrollment of the
first 24 evaluable patients, 10 positive responses (1 CR, 9 PR)
were documented; thus, 39 additional patients were recruited
to complete the study.
1) Overall response (including primary tumour) according
to INRC
Following two courses of TVD, four patients (6.4%) achi-
eved a CR and 28 any PR (44.4%), for an overall RR of 50.8%
(95% CI, 37.9 to 63.6). Of the remaining patients, 16 had a MR
(25.4%); 14, a SD (22.2%); and 1, a PD (1.6%).
2) Achievement of SIOPEN HR-NBL criteria to proceed to
HDT
In addition to the four patients who achieved an overall CR,
14 of the 28 children achieved an overall PR, 10 achieved a
metastatic CR and four GPR. Moreover, of the 16 children with
an overall MR, three had a metastatic CR and two a GPR.
Therefore, 23 patients (36.5%; 95% CI, 24.7 to 49.6; 17 CR and
6 GPR with ! 3 mIBG skeletal areas and no bone marrow dis-
ease) were eligible to proceed to HDT according to the
SIOPEN criteria. 
Table 3 reports on the metastatic response after TVD strati-
fied by metastatic response after rapid COJEC. Of the 46 chil-
dren who entered the study with a PR after rapid COJEC, 20
(43.4%; 14 in CR and six in PR with ! 3 mIBG spots) became
eligible for HDT, as compared to only three of the 17 who 
entered the study (18.8%)  with either SD or PD, p=0.059. 
The response after TVD is reported in Table 2 after stratifi-
cation by site of metastatic disease. Overall, seven CR (70%)
were documented in the 10 patients with only bone marrow
disease, five CR and six PR with ! 3 mIBG skeletal spots (44%)
were documented in the 25 children with only mIBG-positive
scan, five CR (18.5%) were documented among the 27 patients
with combined positive metastatic disease, and one SD was
documented in the only child with hepatic disease. The differ-
ence among groups was statistically significant (p=0.012,
Fisher exact test). If the metastatic sites were analyzed sepa-
rately, 17 of the 37 positive bone marrows (45.9%) cleared after
TVD, while only 10 of the 52 skeletal metastases (19.2%)
achieved CR (p=0.007).
MYCN status did not affect the probability of positive 
response to TVD. In fact, among the 55 subjects assessed for
MYCN, the 13 MYCN amplified patients had a RR (CR or any
PR) similar to that of the 42 not amplified (8 [61.5%] vs. 20
[47.6%]; p=0.38, chi-square test). Similarly, six MYCN ampli-
fied (46.1%) became eligible for HDT, while versus 15 of the
not amplified patients (35.7%) (p=0.53, Fisher exact test).
Table 1. Characteristics at diagnosis and at TVD therapy
of 63 patients with refractory metastatic neuroblastoma
after COJEC induction 
Characteristic No. (%)
At diagnosis
Age, median (IQR, mo) 46 (28-69)
Primary tumour site
Abdomen 55 (87.3)
Chest 6 (9.5)
Other 2 (3.2)
Stage 4 63 (100)
MYCN, amplifieda) 13 (23.6)
At study entry
Overall INRC response post-COJEC
PR 40 (63.52)
MR 7 (11.1)
SD 15 (23.8)
PD 1 (1.6)
Metastatic response post-COJEC
PR 46 (73.0)
SD 16 (25.4)
PD 1 (1.6)
Localization of metastatic disease 
at TVD entry
Bone marrow only 10 (15.9)b)
Skeleton only 25 (39.7)c)
Combined bone marrow and skeleton 27 (42.9)b),c)
Liver 1 (1.6)
TVD, topotecan-vincristine-doxorubicin; IQR, interquartile
range; INRC, International Neuroblastoma Response Cri-
teria; PR, partial response; MR, mixed response; SD, stable
disease; PD, progressive disease; mIBG, metaiodobenzyl-
guanidine. a)Based on 55 evaluable cases, b)Total bone mar-
row positive (n=37), c)Total mIBG skeleton positive (n=52).
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Metastatic response after TVD
Eligible to HDT Not eligible to HDT
Site of metastatic disease PR " 3 mIBG  PR > 3 mIBG
CR spots and negative spots and negative MR SD PD
bone marrow bone marrow
Bone marrow only 10 7 (70.0)a) 0 ( 0 ( 0 ( 3 (30.0) 0 (
Skeleton only 25 5 (20.0)b) 6 (24.0) 4 (16.0) 0 ( 10 (40.0) 0 (
Combined bone marrow 27 5 (18.5)a),b) 0 ( 5 (18.5)a) 16 (59.3) 0 ( 1 (3.7)
and skeleton 
Liver 1 0 ( 0 ( 0 ( 0 ( 1 (100) 0 (
Total 63 17 (27.0) 6 (9.5) 9 (14.3) 16 (25.4) 14 (22.2) 1 (1.6)
Table 2. Metastatic response after two courses of TVD by site of metastatic disease at study entry
Values are presented as number (%). Eligibility to HDT: p=0.012 (Fisher exact test). TVD, topotecan-vincristine-doxorubicin;
HDT, high dose therapy; CR, complete response; mIBG, metaiodobenzylguanidine; PR, partial response; MR, mixed response;
SD, stable disease; PD, progressive disease. a)BM cleared, b)Skeleton cleared.  
Metastatic response after TVD
Metastatic response PR " 3 mIBG  PR > 3 mIBG
after COJEC CR spots and negative spots and negative MR SD PD
bone marrow bone marrow
PR 46 (73.0) 14 (30.4) 6 (13.0) 9 (21.7) 10 (21.7) 7 (15.2) 0 (
SD 16 (25.4) 3 (18.8) 0 ( 0 ( 6 (37.5) 7 (43.7) 0 (
PD 1 (1.6) 0 ( 0 ( 0 ( 0 ( 0 ( 1 (100)
Total 63 ( 17 (27.0) 6 (9.5) 9 (14.3) 16 (25.4) 14 (22.2) 1 (1.6)
Table 3. Metastatic response after TVD stratified by metastatic response after COJEC
Values are presented as number (%). Eligibility to HDT: p=0.059 (chi-square test) comparing patients with PR after COJEC vs.
those with < PR. TVD, topotecan-vincristine-doxorubicin; CR, complete response; PR, partial response; mIBG, metaiodobenzyl-
guanidine; MR, mixed response; SD, stable disease; PD, progressive disease.
Table 4. Grade 3-4 toxicity after 126 TVD courses in 63 patients
Toxicity 1st course 2nd course Overall Patients
Hematologic
Neutropenia 55 (87.3) 51 (80.9) 106 (84.1) 57 (90.5)
Thrombocytopenia 54 (85.7) 50 (79.4) 104 (82.5) 58 (92.1)
Anaemia 40 (63.5) 37 (58.7) 77 (61.1) 48 (76.2)
Nonhematologic
Fever > 38°C 29 (46.0) 24 (38.1) 53 (42.1) 38 (60.3)
Mucositis 17 (27.0) 8 (12.7) 25 (19.8) 20 (31.7)
Vomiting 2 (3.2) 1 (1.3) 3 (2.4) 3 (4.8)
Constipation 1 (1.6) 0 (0.0) 1 (0.8) 1 (1.6)
Sensory neuropathy 2 (3.2) 1 (1.6) 3 (2.4) 2 (3.2)
Values are presented as number (%). TVD, topotecan-vincristine-doxorubicin.
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No difference in achieving the eligibility to HDT was 
observed after stratification of patients according to MYCN
status of their primary tumour.
3. Toxicity
All patients received the two planned TVD courses for a
total of 126 evaluable courses. No chemotherapy-related toxic
deaths were reported, and the observed toxicity was mostly
haematological (Table 4). Overall, 106 courses (84.1%; 95% CI,
76.5 to 90.0) were complicated by grade 3 or 4 neutropenia;
104 (82.5%; 95% CI, 74.8 to 88.7) by grade 3 or 4 thrombocy-
topenia and 77 (61.1%; 95% CI, 52.0 to 69.7) by grade 3 or 4
anaemia. Slightly more toxicities were observed after the first
course (not significant). Only six (9.5%), five (7.9%), 15 (23.8%),
and four (6.4%) patients showed no evidence of neutropenia,
thrombocytopenia, anaemia or any haematological toxicity,
respectively.
Fever was the most frequently reported non-haematological
complication documented after 53 courses (42.1%; 95% CI, 33.3
to 51.2). Hospitalization for systemic antibiotic therapy was 
required following 43 courses (34.1%; 95% CI, 25.9 to 43.1); 25
(39.7%; 95% CI, 27.6 to 52.8) after the first and 18 (28.6%; 95%
CI, 17.9 to 41.3) after the second course. Most episodes of fever
(48 [90.6%; 95% CI, 79.3 to 97.9]) were classified as fever of 
unknown origin, and only five (9.4%; 95% CI, 3.1 to 20.7) as
documented infection (with one case of bacteraemia that was
central venous catheter-related). Stomatitis was the second
most common nonhaematological toxicity occurring after 25
courses (19.8%; 95% CI, 13.3 to 27.9) in 20 patients (31.7%). 
Severe vomiting (grade 3 or 4) was reported after three courses
(2.4%; 95% CI, 0.5 to 6.8) in three patients, and severe sensory
neuropathy occurred after three courses (3.2%; 95% CI, 0.5 to
6.8) in two patients. Only one case (0.8%; 95% CI, 0.02 to 4.3)
of grade 4 constipation was documented.
A 30% dose reduction of the second TVD course was sched-
uled for the patient with grade 4 constipation. There was a
25% dose reduction in three of the 25 patients with severe
stomatitis, and vincristine was only reduced by 50% in two
children with severe neuropathy after the first course of TVD.  
Discussion
This study provides further evidence of the efficacy of TVD
in metastatic neuroblastoma failing to achieve a metastatic
CR after rapid COJEC (which does not include topotecan or
doxorubicin) according to the SIOPEN HR-NBL-1 protocol.
A previous Italian phase II study demonstrated that this
combination is effective for treatment of refractory and 
relapsed (stage 3 and 4) disease, leading to a combined 64%
CR and PR RR [8]. The TVD combination was designed
based on pre-clinical studies demonstrating that topoiso-
merase I (campothecins) and II (doxorubicin) inhibitors, if
administered in this sequence, have synergistic effects with-
out increased toxicity. In addition, the therapeutic effects of
combining topotecan with vincristine were greater than the
additive effect of the agents alone with moderate toxicity 
[12-14]. In the current study, we showed that two courses of
TVD improved the response of 36.5% of patients with high-
risk neuroblastoma who failed to achieve the SIOPEN HR-
NBL criteria after first-line therapy with rapid COJEC, and
that these patients are then eligible to proceed to HDT.  
In our series, the bone marrow was more likely to be
cleared of tumour burden than the skeletal disease. Similarly,
patients who entered TVD after having already demon-
strated some response to COJEC tended to have a better RR
than those who entered TVD after having experienced only
SD or PD.
The results reported herein are not fully comparable with
those from previous studies that also used topotecan in high-
risk neuroblastoma, mainly because of differences in patient
selection and schedule of drug administration. In particular,
this study only comprised patients with PR, MR, SD, or PD
after first-line therapy, while most other studies included 
patients with both relapsed and refractory disease [15-23].
These previous studies generally reported small and hetero-
geneous series that received topotecan either alone [15-19]
with response rates ranging from < 20% to 60%, or in combi-
nation with other drugs including cyclophosphamide [19,20],
temozolomide [21,22], or cyclophosphamide-etoposide [23]
with response rates ranging from 32% to 64%.
To the best of our knowledge, only two other studies have
focused on previously untreated neuroblastoma patients in
which topotecan was administered in combination with 
cyclophosphamide at two different dosages, and the repor-
ted response rates were 76% [24] and 84% [25], respectively.
TVD is a manageable therapeutic regimen. In our study,
no toxic deaths were observed and schedule reduction was
only necessary in six subjects. Myelosuppression was the
main treatment-related toxicity. Although hospitalisation for
systemic antibiotic therapy was required after 34% of the
courses, documented infection was only reported in five 
patients.
In conclusion, this multi-centre European phase II study
demonstrated that the combination of topotecan, vincristine
and doxorubicin increased the RR in 36.5% of patients with
persistent or refractory high-risk neuroblastoma disease
when following an intensive multi-agent induction chemo-
therapy that does not include topotecan or doxorubicin. Chil-
dren with only bone marrow disease and those who had
already shown some chemo-sensitivity to induction therapy
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are more likely to benefit from TVD.
Based on the results of this study and because doxorubicin
and topotecan are not included in the COJEC regimen, we
conclude that the TVD regimen has a role in improving the
RR to COJEC induction therapy and thereby in increasing
the number of patients eligible for HDT according to the
SIOPEN HR-NBL-1 protocol criteria. The long term benefits
of TVD compared to other first line chemotherapy combina-
tions need to be determined in randomized clinical trials. 
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